Silence Therapeutics Plc Stock Performance
| SLN Stock | USD 5.01 0.56 12.58% |
The entity has a beta of 0.35, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Silence Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Silence Therapeutics is expected to be smaller as well. At this point, Silence Therapeutics PLC has a negative expected return of -0.31%. Please make sure to validate Silence Therapeutics' jensen alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Silence Therapeutics PLC performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Silence Therapeutics PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in March 2026. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 12.58 | Five Day Return 15.44 | Year To Date Return (18.54) | Ten Year Return (74.31) | All Time Return (74.31) |
1 | Acquisition by Griffiths Richard Ian of 22632 shares of Silence Therapeutics at 4.5 subject to Rule 16b-3 | 12/02/2025 |
2 | Is Silence Therapeutics plc Depositary Receipt stock attractive for growth ETFs - Index Update AI Driven Price Forecasts - Newser | 12/04/2025 |
3 | Insider Trading | 12/12/2025 |
4 | Silence Therapeutics CEO Craig Tooman steps down - Seeking Alpha | 12/15/2025 |
5 | Acquisition by Ede-golightly James of 90000 shares of Silence Therapeutics at 2.15 subject to Rule 16b-3 | 12/22/2025 |
6 | Silence Therapeutics PLC Sponsored ADR Receives Average Recommendation of Hold from Analysts - MarketBeat | 12/24/2025 |
7 | Acquisition by Lemus David of 90000 shares of Silence Therapeutics at 2.05 subject to Rule 16b-3 | 01/02/2026 |
8 | Acquisition by Ede-golightly James of 90000 shares of Silence Therapeutics at 2.05 subject to Rule 16b-3 | 01/06/2026 |
9 | Will Silence Therapeutics plc stock top growth indexes - Sell Signal AI Enhanced Trading Alerts - ulpravda.ru | 01/08/2026 |
10 | H.C. Wainwright reiterates Buy rating on Silence Therapeutics stock at 75 - Investing.com | 01/23/2026 |
11 | Acquisition by Griffiths Richard Ian of 75266 shares of Silence Therapeutics at 3.97 subject to Rule 16b-3 | 01/26/2026 |
12 | Revenues Working Against Silence Therapeutics plcs Share Price Following 27 percent Dive | 02/05/2026 |
13 | Acquisition by Griffiths Richard Ian of 34309 shares of Silence Therapeutics at 3.66 subject to Rule 16b-3 | 02/13/2026 |
| Begin Period Cash Flow | 68.8 M | |
| Total Cashflows From Investing Activities | -22 M |
Silence Therapeutics Relative Risk vs. Return Landscape
If you would invest 643.00 in Silence Therapeutics PLC on November 19, 2025 and sell it today you would lose (142.00) from holding Silence Therapeutics PLC or give up 22.08% of portfolio value over 90 days. Silence Therapeutics PLC is generating negative expected returns assuming volatility of 4.5498% on return distribution over 90 days investment horizon. In other words, 40% of stocks are less volatile than Silence, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Silence Therapeutics Target Price Odds to finish over Current Price
The tendency of Silence Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 5.01 | 90 days | 5.01 | about 87.07 |
Based on a normal probability distribution, the odds of Silence Therapeutics to move above the current price in 90 days from now is about 87.07 (This Silence Therapeutics PLC probability density function shows the probability of Silence Stock to fall within a particular range of prices over 90 days) .
Silence Therapeutics Price Density |
| Price |
Predictive Modules for Silence Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Silence Therapeutics PLC. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Silence Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Silence Therapeutics is not an exception. The market had few large corrections towards the Silence Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Silence Therapeutics PLC, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Silence Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.37 | |
β | Beta against Dow Jones | 0.35 | |
σ | Overall volatility | 0.77 | |
Ir | Information ratio | -0.09 |
Silence Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Silence Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Silence Therapeutics PLC can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Silence Therapeutics generated a negative expected return over the last 90 days | |
| Silence Therapeutics has high historical volatility and very poor performance | |
| Silence Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 43.26 M. Reported Net Loss for the year was (36.19 M) with profit before taxes, overhead, and interest of 23.59 M. | |
| Silence Therapeutics PLC has about 51.56 M in cash with (67.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72. | |
| Roughly 24.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from simplywall.st: Revenues Working Against Silence Therapeutics plcs Share Price Following 27 percent Dive |
Silence Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Silence Stock often depends not only on the future outlook of the current and potential Silence Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Silence Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 15.4 M | |
| Cash And Short Term Investments | 147.3 M |
Silence Therapeutics Fundamentals Growth
Silence Stock prices reflect investors' perceptions of the future prospects and financial health of Silence Therapeutics, and Silence Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Silence Stock performance.
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (2.50) % | ||||
| Operating Margin | (148.81) % | ||||
| Current Valuation | 124.71 M | ||||
| Shares Outstanding | 47.23 M | ||||
| Price To Book | 2.84 X | ||||
| Price To Sales | 8.14 X | ||||
| Revenue | 43.26 M | ||||
| Gross Profit | 23.59 M | ||||
| EBITDA | (48.99 M) | ||||
| Net Income | (36.19 M) | ||||
| Cash And Equivalents | 51.56 M | ||||
| Cash Per Share | 1.72 X | ||||
| Total Debt | 117 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 3.76 X | ||||
| Book Value Per Share | 1.57 X | ||||
| Cash Flow From Operations | (67.64 M) | ||||
| Earnings Per Share | (1.35) X | ||||
| Market Capitalization | 326.86 M | ||||
| Total Asset | 202.63 M | ||||
| Retained Earnings | (474.04 M) | ||||
| Working Capital | 170.54 M | ||||
About Silence Therapeutics Performance
By examining Silence Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Silence Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Silence Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (105.38) | (110.65) | |
| Return On Tangible Assets | (0.27) | (0.28) | |
| Return On Capital Employed | (0.39) | (0.41) | |
| Return On Assets | (0.26) | (0.27) | |
| Return On Equity | (0.39) | (0.41) |
Things to note about Silence Therapeutics PLC performance evaluation
Checking the ongoing alerts about Silence Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Silence Therapeutics PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Silence Therapeutics generated a negative expected return over the last 90 days | |
| Silence Therapeutics has high historical volatility and very poor performance | |
| Silence Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 43.26 M. Reported Net Loss for the year was (36.19 M) with profit before taxes, overhead, and interest of 23.59 M. | |
| Silence Therapeutics PLC has about 51.56 M in cash with (67.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72. | |
| Roughly 24.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from simplywall.st: Revenues Working Against Silence Therapeutics plcs Share Price Following 27 percent Dive |
- Analyzing Silence Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Silence Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Silence Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Silence Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Silence Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Silence Therapeutics' stock. These opinions can provide insight into Silence Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silence Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Biotechnology sector continue expanding? Could Silence diversify its offerings? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Silence Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.35) | Revenue Per Share | Quarterly Revenue Growth (0.89) | Return On Assets | Return On Equity |
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Silence Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.